KR960040376A - Nephrotic bleeding fever vaccine and preparation method thereof - Google Patents

Nephrotic bleeding fever vaccine and preparation method thereof Download PDF

Info

Publication number
KR960040376A
KR960040376A KR1019950014449A KR19950014449A KR960040376A KR 960040376 A KR960040376 A KR 960040376A KR 1019950014449 A KR1019950014449 A KR 1019950014449A KR 19950014449 A KR19950014449 A KR 19950014449A KR 960040376 A KR960040376 A KR 960040376A
Authority
KR
South Korea
Prior art keywords
vaccine
cfc76
fever vaccine
prepared
protamine sulfate
Prior art date
Application number
KR1019950014449A
Other languages
Korean (ko)
Inventor
유왕돈
김현수
노갑수
이성희
신영철
백영옥
손정진
이상옥
Original Assignee
김정순
제일제당 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김정순, 제일제당 주식회사 filed Critical 김정순
Priority to KR1019950014449A priority Critical patent/KR960040376A/en
Publication of KR960040376A publication Critical patent/KR960040376A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 불활화시킨 신규의 한탄바이러스 CFC76-118(기탁번호: KCTC 0163 BP)로부터 제조된 신증후출혈열백신에 관한 것이다. 또한, 본 발명은 신규바이러스 CFC76-118을 대량으로 배양 및 증식시키고 프로타민설페이트 처리를 통해 1차 정제한 다음, 불활화공정을 수행하고 다시 초원심분리법에 의해 2차 정제를 수행하여 신증후 출혈열백신을 제조하는 방법에 관한 것이다.The present invention relates to nephrotic bleeding fever vaccine prepared from a novel inactivated Hantan virus CFC76-118 (Accession No .: KCTC 0163 BP). In addition, the present invention is cultured and propagated in a large amount of novel virus CFC76-118, and purified first through protamine sulfate treatment, then inactivated process and second purification by ultracentrifugation again nephrotic syndrome hemorrhagic fever vaccine It relates to a method of manufacturing.

Description

신증후출혈열 백신 및 그의 제조방법Nephrotic syndrome hemorrhagic fever vaccine and preparation method thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 한탄바이러스 CFC76-118의 계대력을 나타낸 그래프이다.1 is a graph showing the passage of the hantan virus CFC76-118.

Claims (10)

한탄바이러스 CFC76-118(기탁번호: KCTC 0163 BP)을 증식시키고 프로타민설페이트 처리를 통해 1차정제한 다음, 불활화공정을 수행하고 다시 초원심분리법에 의해 2차 정제를 수행하여 신증후 출혈열 백신을 제조하는 방법.Nephrotic hemorrhagic fever vaccine was prepared by propagating Hantan virus CFC76-118 (Accession No .: KCTC 0163 BP), performing primary purification through protamine sulfate treatment, performing inactivation process, and performing secondary purification by ultracentrifugation. How to. 제1항에 있어서, 바이러스의 증식공정이 생쥐의 뇌에서 이루어지는 방법.The method of claim 1, wherein the virus propagation step is in the brain of a mouse. 제2항에 있어서, 채취된 생쥐의 뇌를 1/75 M PBS 용액(pH 7.2, 5mM EDT A)에 현탁시키는 방법.The method of claim 2, wherein the brains of the harvested mice are suspended in 1/75 M PBS solution (pH 7.2, 5 mM EDT A). 제1항에 있어서, 프로타민 설페이트 처리법이 0.5내지 0.7㎎/㎖의 프로타민설페이트 농도에서 교반시킨다음 한외마쇄기로 분쇄하는 과정으로 구성된방법.The method according to claim 1, wherein the protamine sulfate treatment is performed by stirring at a protamine sulfate concentration of 0.5 to 0.7 mg / ml and then grinding with an ultra-crusher. 제1항에 있어서, 불활화가 0.025% 농도의 포름알데히드 처리에 의해서 수행되는 방법.The method of claim 1 wherein the inactivation is carried out by formaldehyde treatment at a concentration of 0.025%. 제1항에 있어서, 초원심분리법이 60% 3㎖, 35% 3㎖, 20% 18㎖ 수크로오스 구배를 이용하여 수행되는 방법.The method of claim 1, wherein the ultracentrifugation method is performed using 60% 3ml, 35% 3ml, 20% 18ml sucrose gradient. 불활화시킨 한탄 바이러스 CFC76-118(기탁번호: KCTC 0163 BP)로 부터 제조된 신증후출혈열 백신.Nephrotic bleeding fever vaccine prepared from inactivated hantan virus CFC76-118 (Accession No .: KCTC 0163 BP). 제7항에 있어서, 제1항의 제조방법에 의해 제조된백신.8. A vaccine according to claim 7, prepared by the method of claim 1. 제7항에 있어서, 약제학적으로 허용되는 보조제를 함유하는 백신.8. The vaccine of claim 7, which contains a pharmaceutically acceptable adjuvant. 제9항에 있어서, 약제학적으로 허용되는 보조제가 알루미늄하이드록사이드겔, 치메로살, 정제젤라틴 중에서 선택된 1종이상인 백신.The vaccine of claim 9, wherein the pharmaceutically acceptable adjuvant is at least one selected from aluminum hydroxide gels, chimerosal, and purified gelatin. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950014449A 1995-05-31 1995-05-31 Nephrotic bleeding fever vaccine and preparation method thereof KR960040376A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950014449A KR960040376A (en) 1995-05-31 1995-05-31 Nephrotic bleeding fever vaccine and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950014449A KR960040376A (en) 1995-05-31 1995-05-31 Nephrotic bleeding fever vaccine and preparation method thereof

Publications (1)

Publication Number Publication Date
KR960040376A true KR960040376A (en) 1996-12-17

Family

ID=66525403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950014449A KR960040376A (en) 1995-05-31 1995-05-31 Nephrotic bleeding fever vaccine and preparation method thereof

Country Status (1)

Country Link
KR (1) KR960040376A (en)

Similar Documents

Publication Publication Date Title
ATE453403T1 (en) HOST CELL CONTAINING A RECOMBINANT VIRUS THAT EXPRESSES AN ANTIGEN AND A RECOMBINANT VIRUS THAT EXPRESSES AN IMMUNO-STIMULATORY MOLECULE
CA2234208A1 (en) Influenza vaccine
US7745598B2 (en) CpG single strand deoxynucleotides for use as adjuvant
DK1358319T3 (en) Live influenza vaccine and its method of preparation
HUP0102478A2 (en) Particles of hcv envelope proteins: use for vaccination
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
EA199700413A1 (en) COMPOSITION CONTAINING A VACCINE AND ANTIGEN AND POLYACHARIDE CONJUGATE ADSORBED ON ALUMINUM PHOSPHATE
ATE384785T1 (en) PRODUCTION OF VIRUSES, VIRUS ISOLATES, AND VACCINES
ECSP024257A (en) OLD PROTEINS OF THE VIRUS DISEASE OF THE WHITE SPOT DISEASE IN THE SHRIMP AND USES OF THE SAME
PE72699A1 (en) ROTAVIRUS ANTIGEN, VACCINE AND DIAGNOSTIC AGENT FOR ROTAVIRUS INFECTION AND A METHOD TO PRODUCE THE ANTIGEN
KR960040376A (en) Nephrotic bleeding fever vaccine and preparation method thereof
KR960040377A (en) Nephrotic bleeding fever vaccine and preparation method thereof
KR960040378A (en) Nephrotic bleeding fever vaccine and preparation method thereof
ATE283065T1 (en) MULTI-PURPOSE VACCINE AGAINST ENCLOSED VIRUSES
KR960040379A (en) Nephrotic bleeding fever vaccine and preparation method thereof
TW200509964A (en) VP1 of foot-and-mouth disease virus
US4136168A (en) Process for the preparation of neuraminidase from viral sources and methods of utilizing same
Fukada et al. Interference with virus infection induced by RNA in chick embryo cells
KR880000579A (en) Method of producing VeriCella-Joster virus
WO2005014803A1 (en) West nile virus vaccine
KR900007436A (en) Novel Hantan Virus ROK 84/105 Strains and Method for Manufacturing the Hantan Virus Vaccine Using the Same
WO2024029469A1 (en) Method for manufacturing inactivated sars-cov-2 vaccine, inactivated sars-cov-2 vaccine, method for purifying sars-cov-2 or inactivated sars-cov-2, and sars-cov-2 antigen composition or inactivated sars-cov-2 antigen composition
JPS6456620A (en) Production of hemorrhagic fever with renal syndrome virus antigen and vaccine and diagnostic agent using said antigen
World Health Organization Influenza outbreak in the district of Bosobolo, Democratic Republic of the Congo, November—December 2002: Epidemiological report
KR930021778A (en) Novel CUMC-90H1 Virus

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application